<DOC>
	<DOCNO>NCT00541814</DOCNO>
	<brief_summary>The purpose trial ascertain whether withdrawal calcineurin inhibitor ( CNI ) lead less kidney transplant damage compare minimisation . The investigator assess compare degree damage kidney biopsy take minimisation/withdrawal CNI .</brief_summary>
	<brief_title>Calcineurin Inhibitor Minimisation Renal Transplant Recipients With Stable Allograft Function</brief_title>
	<detailed_description>Renal transplantation effective form treatment end-stage renal failure . It double long-term survival major socioeconomic health benefit compare patient remain dialysis . Graft survival UK 90 % one year great 75 % 5 year [ UKTransplant , 2004 ] , good survival graft live donor compare deceased . However , 15 year post-transplantation , 50 % recipient still alive return dialysis . Indeed , premature allograft failure one leading cause end stage renal disease . As short-term outcome renal transplantation continue improve , increase attention pay late attrition renal allograft . It recognise calcineurin inhibitor ( CNI ) nephrotoxicity major factor late renal allograft failure dysfunction . In fact , withdrawal CNI patient deteriorate graft function may improve graft function . However , abundant evidence histological renal allograft damage may progress even absence change renal function - i.e . decline renal function late marker renal damage , therefore institution therapy ( include CNI minimisation ) slow process may `` little , late '' . CNI minimisation may optimise three major route . Firstly , minimise CNI beyond 12 month post transplantation risk acute rejection great . Secondly , perform renal biopsy patient prior CNI minimisation avoid CNI minimisation patient inflammation biopsy . Finally , convert azathioprine mycophenolate prior CNI minimisation renoprotective effect . The type CNI investigate cyclosporine . Patients fulfill study entry criterion require renal allograft biopsy prior randomisation exclude acute rejection , recurrent disease de novo glomerulonephritis . Those patient acceptable biopsy proceed randomisation 1:1 basis 2 group : Group 1 : CNI [ Cyclosporine ] minimisation ; Group 2 : CNI [ Cyclosporine ] withdrawal . At point participant undergo assessment primary secondary outcome measure . The treatment period comprise three stage : Firstly , 2 week period patient stabilise mycophenolate sodium 720mg twice daily ( place azathioprine ) ; Secondly , 3 month period CNI [ Cyclosporine } either target specify low blood level 50-100ng/ml , withdrawn completely ( depend randomisation ) ; Thirdly , 12 month maintenance period new immunosuppression regimen . During first two stage , patient review every 2 week . This 2-weekly follow-up continue first two month third stage study , visit reduce monthly . At visit routine blood urine analysis perform per routine clinical practice . At end third stage study ( i.e . 16 month randomisation ) participant undergo second assessment primary secondary outcome measure . This signify study end individual study participant .</detailed_description>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>The patient must adult recipient first kidney transplant A functioning kidney allograft estimate ( e ) GFR MDRD &gt; 30 ml/min/1.73 m2 , 1 5 year post transplantation Stable allograft function , define great 10 % rise serum creatinine precede 6 month , cyclosporine azathioprine base immunosuppression Minimal proteinuria , evidence urine albumin : creatinine ratio &lt; 50 mg/mmol &gt; = 18 year age Pregnancy suspicion pregnancy confirm positive bHCG pregnancy test Female patient unwilling take effective contraception study duration Untreated ureteric obstruction ultrasound allograft Recurrent urosepsis Severe systemic infection Untreated significant ( &gt; 50 % ) renal artery stenosis magnetic resonance angiography perform prior study History acute allograft rejection History myocardial infarction History malignancy previous 5 year ( exclude nonmelanomatous tumour limit skin ) Symptomatic ischaemic heart disease Hepatitis B surface antigen positive , Hepatitis C positive , HIV positive Recipient combine organ transplantation ( e.g . pancreas/kidney ; liver/kidney ) Recipient ABOincompatible kidney Greater 1 HLA mismatch either `` B '' `` DR '' locus Peak HLA antibody Panel Reactivity ( PRA ) great 10 % Recipient underwent HLA desensitisation procedure prior transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Renal Transplantation</keyword>
	<keyword>Calcineurin Inhibitor</keyword>
	<keyword>Cyclosporine</keyword>
	<keyword>Withdrawal</keyword>
	<keyword>Minimisation</keyword>
</DOC>